Bydureon BCise Dosage
Generic name: EXENATIDE 2mg in 0.85mL
Dosage form: injection, suspension, extended release
Medically reviewed by Drugs.com. Last updated on Dec 2, 2020.
The recommended dose of BYDUREON BCISE is 2 mg subcutaneously once every 7 days (weekly). The dose can be administered at any time of day, with or without meals.
The day of weekly administration can be changed if necessary, as long as the last dose was administered 3 or more days before the new day of administration.
If a dose is missed, administer the dose as soon as noticed, provided the next regularly scheduled dose is due at least 3 days later. Thereafter, patients can resume their usual dosing schedule of once every 7 days (weekly).
If a dose is missed and the next regularly scheduled dose is due 1 or 2 days later, do not administer the missed dose and instead resume BYDUREON BCISE with the next regularly scheduled dose.
- BYDUREON BCISE is intended for patient self-administration. Prior to initiation, train patients on proper mixing and injection technique to ensure the product is adequately mixed and a full dose is delivered [see Instructions for Use].
- Remove the autoinjector from the refrigerator 15 minutes prior to mixing the injection, in order to reach room temperature.
- Mix by shaking vigorously for at least 15 seconds. After mixing, BYDUREON BCISE should appear as an opaque, white to off-white suspension, evenly mixed with no residual medicine along the side, bottom or top of the inspection window.
- Inspect visually for particulate matter and discoloration prior to administration (BYDUREON BCISE contains microspheres which appear as white to off-white particles). Do not use if foreign particulate matter is present or if discoloration is observed. Refer patients to the accompanying Instructions for Use for disposal information [see Instructions for Use].
- Administer BYDUREON BCISE immediately after the autoinjector is prepared as a subcutaneous injection in the abdomen, thigh, or upper arm region. Advise patients to use a different injection site each week when injecting in the same region.
- Do not administer BYDUREON BCISE intravenously or intramuscularly.
- Refer patients to the accompanying Instructions for Use for complete administration instructions with illustrations [see Instructions for Use].
Initiating BYDUREON BCISE Therapy
Prior treatment with an immediate- or extended-release exenatide product is not required when initiating BYDUREON BCISE therapy. Discontinue an immediate- or extended-release exenatide product prior to initiation of BYDUREON BCISE.
Patients changing from immediate-release exenatide to BYDUREON BCISE may experience transient (approximately 2 to 4 weeks) elevations in blood glucose concentrations.
Patients changing from another extended-release exenatide product to BYDUREON BCISE may do so at the next regularly scheduled dose.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Bydureon BCise (exenatide)
- Side Effects
- During Pregnancy or Breastfeeding
- Drug Interactions
- Pricing & Coupons
- En Español
- 29 Reviews
- Drug class: incretin mimetics
- FDA Alerts (2)